RAD51 INHIBITORS Russian patent published in 2023 - IPC C07D277/28 C07D277/30 C07D277/42 C07D417/04 C07D417/12 C07D417/14 A61K31/427 A61P25/28 A61P35/00 A61P37/00 

FIELD: organic chemistry.

SUBSTANCE: heterocyclic compound of the formula below, its pharmaceutically acceptable salt, where the thiazole ring is optionally substituted with -F or -Cl; Cy is -(C₃-C₇)cycloalkyl, bridged (C₆-C₁₂)cycloalkyl, or a 4-6-membered heterocyclic ring containing 1-2 heteroatoms selected from N and O, each of which is optionally substituted with halogen, - OH, (C₁-C₄)alkyl or (C₁-C₄)alkoxy; if X⁵ is connected to the nitrogen atom Cy, X⁵ is absent; if X⁵ is connected to a carbon atom Cy, X⁵ is NR^a or O; X⁶ is NR^a or O; R¹ is (C₁-C₅)alkyl optionally substituted with -OH; R³ is (C₁-C₅)alkyl, -CH₂-phenyl, -(C₃-C₇)cycloalkyl, -CH₂-(C₃-C₇)cycloalkyl, -CH₂-monocyclic 4-5-membered heterocyclic ring containing 1-2 heteroatoms selected from N and O, or a monocyclic 4-5-membered heterocyclic ring containing 1-2 heteroatoms selected from N and O, where -(C₃-C₇)cycloalkyl, phenyl or a monocyclic 4-5-membered heterocyclic ring represented by R³ or in the group represented by R³ is optionally substituted with halogen, -OH, (C₁-C₄)alkyl, halomethyl, halomethoxy, or (C₁-C₄)alkoxy; R² is -NR^aC(O)O(C₁-C₄)alkyl, -NR^aC(O)NR^a(C₁-C₄)alkyl, -NR^aC(O)O-(C₃-C₆)cycloalkyl, -NR^aC(O)NR^a-(C₃-C₆)cycloalkyl, -NR^aC(O)O-monocyclic 4-6-membered heterocyclic ring containing 1-2 heteroatoms, selected from N and O, or -NR^aC(O)NR^a-monocyclic 4-6-membered heterocyclic ring containing 1-2 heteroatoms selected from N and O; where (C₁-C₄)alkyl in the group represented by R² is optionally substituted with halogen, -(C₃-C₆)cycloalkyl, phenyl, a monocyclic 5-6-membered heterocyclic ring containing 1-2 heteroatoms selected from N and O, or a monocyclic 5-6-membered heteroaromatic ring containing 1-2 heteroatoms selected from N and O; where (C₃-C₆)cycloalkyl in the group represented by R² is optionally substituted with halogen, -CH₃ or -OR^a; where the phenyl in the group represented by R² is optionally substituted with halogen, -CH₃ or -OR^a; where the heterocyclic ring in the group represented by R² is optionally substituted with halogen, -OR^a or -CH₃; where the heteroaromatic ring in the group represented by R² is optionally substituted with halogen, -CH₃ or -OR^a ; and each R^a is independently -H or -CH₃. The invention also relates to a pharmaceutical composition based on the above compound, a method for the treatment of diseases associated with RAD51 inhibition.

EFFECT: effective inhibition of RAD51 by the compound of the specified structure in the treatment of cancer, autoimmune diseases, immunodeficiencies or neurodegenerative diseases.

57 cl, 5 tbl, 79 ex